Scott Lentini is a Senior Principal Scientist at Eli Lilly, where they focus on peptide and antibody bioconjugation. They previously held positions at Aileron Therapeutics, ARIAD Pharmaceuticals, and BIND Therapeutics, contributing significantly to drug development projects, including the first in-house developed pan-BCR-ABL inhibitor for chronic myeloid leukemia. Scott earned a BS in Chemistry from the University of Massachusetts Amherst and is currently continuing their education at Clear Rock.
This person is not in the org chart
This person is not in any teams
This person is not in any offices